Physician profile
Hannah E Phillips
NPI 1881035178
$455,401.08
in general payments reported to CMS, 2019-2025
13 companies · $72K in 2025
The $72K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $97K · 2022: $102K · 2023: $52K · 2024: $132K · 2025: $72K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $183K · Travel and Lodging: $54K · Consulting Fee: $11K · Food and Beverage: $8,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $182,855.50 |
| Travel and Lodging | $53,727.18 |
| Consulting Fee | $11,110.00 |
| Food and Beverage | $8,151.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $440,401.97 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| E.R. Squibb & Sons, L.L.C. | $12,234.08 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $2,009.69 | 2021 | |
| Abbvie INC. | $180.53 | 2021-2025 | |
| Corium, LLC | $121.82 | 2023 | Azstarys |
| Acadia Pharmaceuticals INC | $112.00 | 2024 | Nuplazid |
| Alkermes, INC. | $104.17 | 2024 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $102.43 | 2023 | Auvelity |
| Biogen, INC. | $39.95 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $37.10 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $33.01 | 2024 | Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.45 | 2021 | |
| Janssen Scientific Affairs, LLC | $11.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.